Cohance Lifesciences had a difficult beginning to FY27. For the April-June quarter, the firm recorded a consolidated net loss of ₹24.1 crore, a significant shift from the ₹48.9 crore net profit it earned during the same timeframe last year. Operational revenue fell by 23.1% year-on-year to ₹422 crore, and the company's operational results saw a steep drop, with EBITDA plummeting 99% to reach ₹1.2 crore.
by shortkt.com✓